2MD., Assoc. Prof., Bolu Abant Izzet Baysal University, Faculty of Medicine, Department of Ophthalmology, Bolu, Turkey DOI : 10.37845/ret.vit.2020.29.40 Purpose: To evaluate effects of repeated intravitreal injections (IVIs) on vitreous refl ux (VR) and intraocular pressure (IOP) changes in patients receiving intravitreal ranibizumab (IR) treatment.
Materials and Methods: We retrospectively reviewed fi les of patients with wet type age-related macular degeneration or diabetic macular edema patients treated with IR and demographic information0, lens status, IOP values, amount of VR and data regarding intravitreal treatment were recorded in all patients. The study included 74 eyes of 74 patients who had complete data in a least 2 IVI sessions. Data obtained during the first IVI session (IVI1), second IVI session (IVI2) and data from third IVE session in 14 of 74 patients were analyzed.
Results: In the study populations, there were 41 female (55.6%) and the mean age was 68.61 ± 9.81 (43-81) years. The mean number of IR injections was 4.89 ± 2.79 (1-10) and mean time was 7.1 ± 3.7 months (1-24 months) between IVI1 and IVI2. IOP values before and immediately after IVI were signifi cantly higher in the IVI2 session, but there was no significant difference in IOP values on minute 30 after IVI (p: 0.032, <0.001, 0.518, respectively). The extent of IOP elevation after IVI was also signifi cantly higher in IVI2 (p <0.001). The amount of VR was decreased in 44 patients (59.46%) whereas it was increased in 9 patients (12.16%) and no change was detected 21 patients (28.38%). There was no signifi cant relationship between IOP changes after IVI and lens status, diagnosis, age and gender and (p> 0.05 for all data).
Conclusion: It was found that repeated IVI applications decreased the amount of VR and therefore increased the frequency of short-term IOP after IVI.
Keywords : Intraocular pressure, Intravitreal injection, Vitreous refl ux